Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib–fluvoxamine drug-drug interaction study in advanced solid tumors
NL-OMON39285Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dovitinib and fluvoxamine in Nonhematologic neoplasms and hepatocellular carcinoma (HCC), sponsored by Novartis. Primary endpoints: AUC0-72h of dovitinib and Cmax of dovitinib. Planned start Mar 2013; status: not yet recruiting.
02
Drugs
dovitinibfluvoxamine
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON39285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39285.